Peptides are short amino-acid chains (2-50 residues) sitting between small molecules and biologics: highly target-specific, cheap to synthesize, but mostly not orally bioavailable. The evidence is bimodal: GLP-1 agonists are approved drugs with huge phase 3 programs and elamipretide won accelerated FDA approval for Barth syndrome in 2025, while BPC-157, TB-500 and the Russian bioregulators rest on animal data or Russian clinical literature. The dominant practical risk is sourcing, because research peptides have no standardized quality control.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
Which therapeutic peptides are FDA-approved?
GLP-1 agonists like semaglutide and tirzepatide are fully approved with massive phase 3 programs, and elamipretide (SS-31) received accelerated approval for Barth syndrome in 2025. Everything else in this entry is either Russian-approved, like Semax, Selank, Thymalin and Epitalon, or unapproved everywhere.5
Does BPC-157 have human evidence?
Very little. Reviews describe extensive and consistent animal data but very few human trials, leaving a large gap between online enthusiasm and the published record.2
What is the biggest safety risk with peptides?
Supplier quality. Research and compounded peptides have no standardized quality control, so the entry's non-negotiables are 98%+ HPLC purity, mass-spectrometry sequence confirmation, endotoxin testing and accredited third-party labs.
Are Russian peptides like Semax and Epitalon proven?
They are approved and clinically used in Russia with moderate evidence from Russian studies, but they lack Western randomized-trial replication. Khavinson's framework treats short peptides as gene-expression modulators rather than receptor agonists.1
What would change this rating?
Regulatory movement and real trials: the July 2026 PCAC recommended BPC-157, TB-500, MOTS-c, Epitalon, Semax and KPV for the 503A compounding list over FDA staff objections, but the votes are non-binding and FDA rulemaking is still pending.6
Comprehensive guide to therapeutic peptides — the fastest-expanding therapeutic frontier in regenerative medicine, cognitive enhancement, metabolic optimization, and anti-aging. Peptides offer mechanisms unavailable to small molecules or biologics: target specificity, favorable safety profiles, and gene-level regulation.
This section covers the complete therapeutic peptide landscape — from Russian bioregulators (Khavinson's 50-year program) to cutting-edge wound-healing compounds (BPC-157) to cognitive peptides (Semax, Selank) and metabolic regulators (MOTS-C, GLP-1 analogs).
02Why Peptides Are Different
Advantages Over Traditional Therapeutics
| Property | Small Molecules | Biologics | Peptides |
|---|---|---|---|
| Target specificity | Low-moderate | High | Very high |
| Oral bioavailability | Yes | Poor | Limited (some notable exceptions) |
| Manufacturing cost | Low | Very high | Moderate |
| Immunogenicity | Low | Moderate-high | Low |
| Tissue penetration | Good | Poor | Moderate |
| Molecular weight | <500 Da | >5000 Da | 500-5000 Da |
| Synthesis complexity | Simple | Complex | Moderate |
Swipe table →
The Peptide Advantage in Practice
The peptide category occupies a unique pharmacological niche:
- More specific than small molecules — Can target exact receptor subtypes
- Easier to manufacture than biologics — Chemical synthesis, not recombinant
- Better tissue penetration than biologics — Can cross membranes (some)
- Gene-level effects — Russian bioregulators directly modify gene expression
Peptide Categories by Origin
| Source | Examples | Key Characteristic |
|---|---|---|
| Endogenous human | Insulin, oxytocin, ACTH | Identical to human sequences; best safety |
| Synthesized/modified | BPC-157, TB-500, Epitalon | Engineered for stability, potency, bioavailability |
| Animal-derived | GHK-Cu (from albumin), thymosin | Extracted; complex multi-target mechanisms |
| Russian/Soviet-developed | Epitalon, Semax, Selank, Thymalin | Extensive Russian clinical use; unique mechanisms |
Swipe table →
03Quick Reference: Evidence Levels by Peptide
| Peptide | Evidence Level | FDA Status | Primary Mechanism | Risk |
|---|---|---|---|---|
| BPC-157 | Animal studies (extensive) | Not approved | FAK-ERK signaling; angiogenesis | Low |
| TB-500 | Animal studies (strong) | Not approved | Actin regulation; cell migration | Low |
| GHK-Cu | Human studies (moderate) | Not approved | Gene modulation (4000+ genes) | Low |
| SS-31 | Phase 1-3 + approval | ✅ FDA approved (Barth syndrome) | Cardiolipin binding | Low |
| MOTS-C | Preclinical + early human | Not approved | AMPK activation | Low |
| Epitalon | Russian clinical trials | Not approved (Russia: approved) | Telomerase activation | Low |
| Thymalin | Russian clinical trials | ✅ Russian approved | Immune modulation | Low |
| Semax | Russian clinical trials | ✅ Russian approved | BDNF upregulation | Low |
| Selank | Russian clinical trials | ✅ Russian approved | GABA modulation | Low |
| Dihexa | Animal only | Not approved | HGF/c-Met | ⚠️ Cancer concern |
| GLP-1 (Semaglutide) | Multiple RCTs | ✅ FDA approved | GLP-1 receptor agonist | Moderate |
Swipe table →
04Administration Routes Reference
| Route | Peptides | Pros | Cons |
|---|---|---|---|
| Subcutaneous (SC) | Most peptides (BPC-157, TB-500, Epitalon, Thymalin) | Standard systemic delivery; predictable absorption | Requires injection |
| Intramuscular (IM) | TB-500 (sometimes) | Good for local tissue targeting | Less common |
| Intranasal/Spray | Semax, Selank | Bypasses first-pass metabolism; convenient | Some peptides not bioavailable nasally |
| Oral | BPC-157 (unique stability) | Most convenient | Most peptides destroyed in GI tract |
| Topical | GHK-Cu | Local effect; skin applications | Limited systemic effect |
| Sublingual | Some peptides | Bypasses GI and first-pass | Variable absorption |
Swipe table →
05Quality and Sourcing (Critical)
The #1 Risk in Peptide Therapy
Supplier quality varies enormously. Unlike FDA-approved pharmaceuticals, research peptides and compounded peptides have no standardized quality control. This is the single greatest risk factor in peptide therapy.
What to Demand From Any Supplier
| Requirement | Why | How to Verify |
|---|---|---|
| ≥98% purity (HPLC) | Impurities can be harmful | CoA with HPLC data |
| Mass spectrometry | Confirms exact sequence | MS report on request |
| Endotoxin testing | Required for injectables | LAL test or equivalent |
| Lyophilized (freeze-dried) | Stability during shipping/storage | Visual: powder, not liquid |
| Cold chain | Temperature-sensitive | Packaging with cold packs |
| ISO/IEC 17025 lab | Accredited third-party testing | Accreditation number |
Swipe table →
Red Flags
| Red Flag | What It Signals |
|---|---|
| No CoA available | Cannot verify purity |
| Price too low (e.g., $20/vial) | Likely impure or counterfeit |
| "Research use only" with no testing | Marketing, not quality |
| Wrong sequence claimed | Supplier doesn't verify |
| Liquid form (unpreserved) | Degradation risk |
| No refrigeration required | Stability concerns |
Swipe table →
Trusted Source Categories
| Source Type | Examples | Notes |
|---|---|---|
| US compounding pharmacies | Lowest risk; requires prescription | Best for patient safety |
| Reputable research suppliers | Multiple with GMP; CoA required | For experienced users |
| Russian pharmaceutical | Khavinson-origin products | Best for bioregulators specifically |
Swipe table →
06Recommended Reading Order
For Newcomers to Peptides
- Foundation → Overview - Therapeutic Peptides — Categories, evidence levels, regulatory status
- Safety first → Peptide Sources and Quality — How to verify any peptide product
- Protocols → Peptide Protocols and Dosing — General administration guidelines
- → BPC-157 (Body Protection Compound) — Best-studied; oral option
For Specific Applications
| Goal | Start Here | Additional Files |
|---|---|---|
| Wound/tissue healing | BPC-157 (Body Protection Compound) | Peptide Therapy for Injuries |
| Cognitive enhancement | Semax | Selank |
| Anti-aging/longevity | Epitalon | Thymalin, Khavinson Peptides |
| Metabolic/weight | GLP-1 Peptides... | Metabolic Health and Insulin |
| Immune support | Thymalin | Immune Function |
| Mitochondrial | MOTS-C | Mitochondrial Health |
Swipe table →
07Practical Notes
Uses
- Verify quality — Get CoA from supplier before use
- — Test tolerance with lowest dose first
- Track everything — Baseline symptoms, dose, timing, effects, side effects
- Consider oral BPC-157 first — Safest entry point; meaningful evidence
Common Mistakes
| Mistake | Why It Matters |
|---|---|
| Buying cheapest peptides | Purity is everything; impurities are dangerous |
| No cycling | Receptor downregulation; reduced efficacy |
| Stacking too many at once | Can't identify what works |
| Ignoring source quality | Supplier verification is non-negotiable |
| Assuming "natural" = safe | Peptides are biologically active; respect potency |
Swipe table →
08Notes
Regulatory Status by Peptide
| Peptide | US Status | Russian Status | Notes |
|---|---|---|---|
| BPC-157 | Research only | Not approved | Most studied; not approved anywhere |
| TB-500 | Research only | Not approved | Thymosin Beta-4 analog |
| GHK-Cu | Cosmetic use | Not approved | Used in skin care products |
| SS-31 | FDA approved | Not approved | Barth syndrome only |
| MOTS-C | Research only | Not approved | Investigational |
| Epitalon | Research only | Approved | Russian clinical use |
| Thymalin | Not approved | Approved | Russian clinical use |
| Semax | Not approved | Approved | Russian clinical use |
| Selank | Not approved | Approved | Russian clinical use |
| GLP-1 (Semaglutide) | FDA approved | Approved | Mainstream pharmaceutical |
Swipe table →
Future Developments to Watch
- SS-31 (Elamipretide): Phase 3 trials for dry age-related macular degeneration (another indication)
- BPC-157: Growing number of compassionate use cases; no formal clinical trials yet
- Epitalon: Western research interest increasing; telomerase mechanism attracting attention
- MOTS-C: Phase 1 trials underway for metabolic indication
2026 Regulatory Alert (UPDATED 2026-08-19): At the July 23–24, 2026 PCAC meeting, the committee recommended 6 of 7 peptides for the 503A Bulks List: BPC-157 (8–6), KPV (8–6), TB-500, MOTS-c, Epitalon (7–5), Semax (8–5) — all over FDA career-staff objections (characterization, impurities, immunogenicity, insufficient efficacy data). Emideltide/DSIP was rejected (6–7). Votes are non-binding; FDA's final listing decision was still pending as of mid-Aug 2026. Five more peptides (incl. GHK-Cu, LL-37, Dihexa) go to PCAC before Feb 2027. Full analysis: FDA Peptide Reclassification 2026 — Regulatory Intelligence. Current sourcing status unchanged until final rule: largely research/gray market; EU/EMA significantly stricter. Monitor FDA compounding lists before sourcing. See Peptide Sources and Quality.
09Doses in studies
Overview
- Have strict storage requirements (refrigeration, protection from light)
- Are almost always administered subcutaneously or intramuscularly (IM)
⚠️ Disclaimer: These are research protocols. Most peptides discussed here are not FDA-approved. Consult a qualified practitioner.
Required Materials
| Material | Purpose | Notes |
|---|---|---|
| Sterile Sodium Chloride (0.9% NaCl) | Alternative solvent | Single-use; no preservative |
Swipe table →
reconstitution Math
Key formula:
Concentration (mcg/mL) = Total peptide (mcg) ÷ Volume of water (mL)
Dose (mcg) = Concentration (mcg/mL) × Volume to inject (mL)
Common example:
Dosing example for BPC-157:
| Vial Size | Water Added | Concentration |
|---|---|---|
| 5mg | 1mL | 5000 mcg/mL |
| 5mg | 2mL | 2500 mcg/mL |
| 10mg | 2mL | 5000 mcg/mL |
Swipe table →
Subcutaneous
Most common route for therapeutic peptides.
Advantages: - Slow absorption → sustained release effect - Easy self-administration - Minimal pain - Good bioavailability
Intramuscular (IM)
Used for certain peptides (e.g., some growth hormone-releasing peptides).
Oral Administration
Limited to specific peptides with oral bioavailability:
- BPC-157: Stable in gastric juice; documented oral bioavailability
- Selank: Developed as nasal/oral formulation
- Semax: Originally developed as nasal formulation
Note: Most therapeutic peptides are NOT orally bioavailable due to degradation in the gastrointestinal tract.
Nasal Administration
Used for peptides targeting CNS effects:
- Semax/Semax nasal
- Selank
- DIhexa (experimental)
Procedure: - Use dedicated nasal spray bottles - Tilt head back slightly - Spray into nostril - Avoid sniffing (pulls medication to stomach)
TB-500 (Thymosin Beta-4)
Notes: - Often combined with BPC-157 in "BP-500" blend - Not FDA-approved; no established human dose
Thymosin Alpha-1 (Immunomodulator)
Clinical data: Thymosin Alpha-1 has FDA approval (as Zadaxin) in 35+ countries for: - Chronic hepatitis B and C - HIV/AIDS - Certain cancers (as adjuvant therapy) - COVID-19 (investigational)
Source: PMID 32448923, PMID 10821397
Thymalin (Thymus Extract Peptide)
Source: Russian clinical practice; limited Western data. See Thymalin for details.
GLP-1 Agonists (Semaglutide, Tirzepatide)
| Peptide | Escalation | Maintenance |
|---|---|---|
| Semaglutide (Ozempic) | Every 4 weeks | — |
| Semaglutide (Wegovy) | Every 4 weeks | — |
| Tirzepatide (Mounjaro) | Every 4 weeks | — |
Swipe table →
Note: GLP-1 peptides are FDA-approved pharmaceuticals with established dosing protocols. See GLP-1 Peptides (Semaglutide, Tirzepatide, Retatrutide) for detailed information.
Approaches Reported in the Literature
| Peptide Type | Notes |
|---|---|
| BPC-157 | Generally safe to use continuously |
| TB-500 | Growth promotion plateaus |
| Thymosin Alpha-1 | Immune system assessment |
| GH secretagogues | IGF-1 normalization |
| GHRP-2/GHRP-6 | Receptor desensitization |
Swipe table →
Uses
Some peptides are used in "pulsing" fashion — high-dose administration once weekly rather than daily:
| Peptide | Application |
|---|---|
| TB-500 | Maintenance therapy |
| BPC-157 | Systemic support |
Swipe table →
Side Effects by Category
| Category | Common Side Effects | Notes |
|---|---|---|
| Immune-stimulating | Flu-like symptoms | Thymosin family; usually mild |
| GH/IGF-1 affecting | Water retention, numbness | Monitor; dose-dependent |
| Gastrointestinal | Nausea, diarrhea | Especially GLP-1 agonists |
Swipe table →
Contraindications
Relative contraindications: - Pregnancy/breastfeeding (insufficient data) - Active cancer (some peptides may affect growth) - Autoimmune conditions (immune-modulating peptides) - Organ transplantation (immunosuppression concerns)
Drug Interactions
| Interaction | Effect | Recommendation |
|---|---|---|
| Immunosuppressants | Countereffects | Avoid or adjust |
| Anticoagulants | Bleeding risk (wound healing peptides) | Monitor closely |
| NSAIDs | Additive GI effects (BPC-157 may be protective) | Usually compatible |
| Growth hormone | Additive effects | Avoid or monitor IGF-1 |
Swipe table →
Quality and Sourcing
Critical: Peptide quality varies dramatically by source. See Peptide Sources and Quality for detailed guidance.
Red Flags
⚠️ Warning signs of poor quality: - Price too low to be plausible - No certificate of analysis (COA) - No third-party testing - Unverifiable manufacturer - Inconsistent appearance between orders - Claims that seem too good to be true
Quality Markers
✅ What to look for: - Third-party lab testing - COA available on request - GMP-certified manufacturer - Proper packaging (glass vial, not plastic) - Adequate cold chain - Batch numbers traceable
Storage Guidelines
| Form | Storage | Duration | Notes |
|---|---|---|---|
| Lyophilized powder | 2-8°C (refrigerated) | 2-3 years | Protect from moisture |
| Lyophilized powder | -20°C (frozen) | Extended | Best for long-term |
Swipe table →
Stability Factors
- Light: Protect from UV exposure
- Time: Discard after stability window
10Connections
11Sources
- PubMed 25940644PubMed 25940644
- PubMed 31692455PubMed 31692455
- PubMed 27824938PubMed 27824938
- PubMed 28753712PubMed 28753712
- PubMed 29406255PubMed 29406255
- PubMed 32040947PubMed 32040947
- PubMed 32448923PubMed 32448923
- PubMed 10821397PubMed 10821397
12Entry history
Latest content update.
Folded in 1 earlier page: peptide-doses-in-research.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.